Nom du produit:5-bromo-1,3-thiazol-2-amine

IUPAC Name:5-bromo-1,3-thiazol-2-amine

CAS:3034-22-8
Formule moléculaire:C3H3BrN2S
Pureté:97%
Numéro de catalogue:CM104786
Poids moléculaire:179.04

Unité d'emballage Stock disponible Prix($) Quantité
CM104786-25g in stock ŗŹ
CM104786-100g in stock IJľľ
CM104786-500g in stock ůǤȃ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:3034-22-8
Formule moléculaire:C3H3BrN2S
Point de fusion:-
Code SMILES:NC1=NC=C(Br)S1
Densité:
Numéro de catalogue:CM104786
Poids moléculaire:179.04
Point d'ébullition:
N° Mdl:MFCD00016893
Stockage:

Category Infos

Thiazoles
Thiazoles are very important functional groups in medicinal chemistry. They act as ligands on a variety of biological matrices. Thiazoles are used in a wide range of therapeutic applications, such as antibacterial, antiretroviral, antifungal, antiallergic, antihypertensive, pain treatment, and to control symptoms of schizophrenia.

Column Infos

Cadisegliatin
vTv Therapeutics announces FDA submission for first phase 3 study of Cadisegliatin in patients with type 1 diabetes. Cadisegliatin (TTP399) is developed as an adjunctive therapy to insulin for the treatment of type 1 diabetes, and the phase 3 trial evaluates its safety and efficacy.
Glucokinase (GK) is mainly concentrated in liver cells, and involved in the regulation of glucose metabolism. Cadisegliatin (TTP399) is a liver-selective glucosekinase activator with a mechanism of action different from that of antidiabetic drugs. It binds to the allosteric site of GK and restores innate glucose-regulating capacity of the liver, not disrupting the interaction between GK and GKRP. Cadisegliatin previously received a Breakthrough Therapy designation from the U.S. FDA.